title: New and treatment-relevant risk stratification for thrombosis in essential thrombocythemia and polycythemia vera.
authors: Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, Minnesota.
authors: Ayalew
authors: A
authors: Tefferi
authors: Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.
authors: Tiziano
authors: T
authors: Barbui
mesh_terms: D000367:Age Factors; D000368:Aged; D001241:Aspirin / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D053614:Janus Kinase 2 / Q000235:genetics; D008875:Middle Aged; D009154:Mutation; D018579:Patient Selection; D018962:Phlebotomy; D011087:Polycythemia Vera / Q000097:blood / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D012306:Risk; D018570:Risk Assessment; D013920:Thrombocythemia, Essential / Q000097:blood / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D013927:Thrombosis / Q000097:blood / Q000235:genetics / Q000473:pathology / Q000517:prevention & control*
chemical_list: D004791:Enzyme Inhibitors; D005343:Fibrinolytic Agents; C507924:JAK2 protein, human; D053614:Janus Kinase 2; D001241:Aspirin; D006918:Hydroxyurea